Merrimack Pharmaceuticals, Inc.

MACK

US5903282094

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
14.73 ^USD	0.00%		+0.07%	+9.84%

Mar. 27	Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	MT
Mar. 07	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell Small Cap Completeness Index

June 23, 2023 at 12:00 am EDT

Latest news about Merrimack Pharmaceuticals, Inc.

Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27	MT
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	Feb. 14	MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing	Nov. 16	MT
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to S&P Global BMI Index	23-09-18	CI
Insider Buy: Merrimack Pharmaceuticals	23-08-09	MT
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000E Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell Small Cap Completeness Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2500 Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000 Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2000 Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000 Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2000 Dynamic Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000E Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2500 Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell Small Cap Comp Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2000 Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Insider Buy: Merrimack Pharmaceuticals	23-03-22	MT
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Insider Buy: Merrimack Pharmaceuticals	23-02-01	MT
Insider Buy: Merrimack Pharmaceuticals	23-01-31	MT

Chart Merrimack Pharmaceuticals, Inc.

Duration

Period

More charts

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The Company is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Companyâs wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MERRIMACK PHARMACEUTICALS, INC.	+9.84%	214M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B